1. Trimbos B, Timmers Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. Kim WY, Choi JS, Park CS, Kim BG, Lee JH, Bae DS. An analysis of clinicopathologic prognostic factors affecting survival in patients with epithelial ovarian cancer. Korean J Obstet Gynecol 2002;45:1800-1807.
4. Park HM, Kim YS, Shin EK, Kim MK, Jung KA, Park MH, Chun SH, Ahn JJ, Kim CI, Kim SC. The ability of preoperative serum CA-125 level to predict the outcome of primary cytoreductive surgery of epithelial ovarian carcinoma. Korean J Gynecol Oncol Colposc 2003;14:158-166.
5. Kim SC. Consolidation and maintenance therapy for patients with advanced epithelial ovarian cancer. Korean J Obstet Gynecol 2005;48:2261-2284.
6. No JH, Park YS, Kim SM, Chung HH, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Pattern of care: epithelial ovarian cancer in case of incomplete previous surgery. Korean J Gynecol Oncol 2007;18:195-200.
7. Le T, Adolph A, Krepart GV, Lotocki R, Heywood MS. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol 2002;85:351-355.
8. Yun JH, Lee HY, Park HW, Shin JW, Lee JM, Park CY. The analysis of prognostic factors in patients with epithelial ovarian cancer. Korean J Obstet Gynecol 2006;49:566-571.
10. Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining ‘optimal’ residual disease. Gynecol Oncol 2012;125:483-492.
12. Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 2006;7:925-934.
15. Othersen HB Jr. Ephraim McDowell: the qualities of a good surgeon. Ann Surg 2004;239:648-650.
16. Tait L. The pathology and treatment of disease of the ovaries. New York: William Wood & Co; 1883.
17. Pemberton FA. Carcinoma of the ovary. Am J Obstet Gynecol 1940;40:751-763.
18. Munnell EW. The changing prognosis and treatment in cancer of the ovary: a report of 235 patients with primary ovarian carcinoma 1952-1961. Am J Obstet Gynecol 1968;100:790-805.
19. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-104.
20. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-979.
21. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a metaanalysis. J Clin Oncol 2002;20:1248-1259.
22. Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, Smith JP. Staging laparotomy in early ovarian cancer. JAMA 1983;250:3072-3076.
23. Grabowski JP, Harter P, Buhrmann C, Lorenz D, Hils R, Kommoss S, Traut A, du Bois A. Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO I-IIIA after sub-standard initial surgery. Surg Oncol 2012;21:31-35.
25. Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E. participants of 4th Ovarian Cancer Consensus Conference (OCCC); Gyne- cologic Cancer Intergroup. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011;21:750-755.
26. Kim HS, Ahn JH, Chung HH, Kim JW, Park NH, Song YS, Lee HP, Kim YB. Impact of intraoperative rupture of the ovarian capsule on prognosis in patients with early-stage epithelial ovarian cancer: a meta-analysis. Eur J Surg Oncol 2013;39:279289.
27. Zuna RE, Behrens A. Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients. J Natl Cancer Inst 1996;88:980-987.
28. Powless CA, Bakkum-Gamez JN, Aletti GD, Cliby WA. Random peritoneal biopsies have limited value in staging of appa- rent early stage epithelial ovarian cancer after thorough exploration. Gynecol Oncol 2009;115:86-89.
30. Skipper HE. Adjuvant chemotherapy. Cancer 1978;41:936-940.
31. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.
32. Curt GA, Clendeninn NJ, Chabner BA. Drug resistance in cancer. Cancer Treat Rep 1984;68:87-99.
33. Skipper HE. Thoughts on cancer chemotherapy and combination modality therapy (1974). JAMA 1974;230:1033-1035.
34. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979;39:3861-3865.
35. Hacker NF. Controversial aspects of cytoreductive surgery in epithelial ovarian cancer. Baillieres Clin Obstet Gynaecol 1989;3:49-57.
36. Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1989;7:457-465.
37. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998;69:103-108.
38. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103:559-564.
39. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, Podratz KC, Cliby WA. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006;107:77-85.
40. Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP; Gynecologic Oncology Group Study. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621-3627.
41. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe dʼInvestigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009;115:1234-1244.
43. Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for ad- vanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 2013;130:493-498.
45. Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial J Clin Oncol 2005;23:8802-8811.
47. Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP; Gynecologic Oncology Group. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2008;26:83-89.
49. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival: an exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2007;106:69-74.
50. Bristow RE, Chang J, Ziogas A, Campos B, Chavez LR. AntonCulver H. Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival. J Am Coll Surg 2015;220:940-950.